Join

Compare · AORT vs MDLN

AORT vs MDLN

Side-by-side comparison of Artivion Inc. (AORT) and Medline Inc. (MDLN): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both AORT and MDLN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
  • MDLN is the larger of the two at $48.00B, about 48.3x AORT ($993.7M).
  • Over the past year, AORT is down 29.5% and MDLN is down 10.4% - MDLN leads by 19.1 points.
  • MDLN has been more active in the news (21 items in the past 4 weeks vs 16 for AORT).
  • MDLN has more recent analyst coverage (25 ratings vs 8 for AORT).
PerformanceAORT-56.65%MDLN-10.36%
2025-12-17+0.00%2026-06-10
MetricAORTMDLN
Company
Artivion Inc.
Medline Inc.
Price
$20.46-2.11%
$36.53+1.46%
Market cap
$993.7M
$48.00B
1M return
-14.11%
-6.93%
1Y return
-29.50%
-10.36%
Industry
Medical/Dental Instruments
Medical/Dental Instruments
Exchange
NYSE
NASDAQ
IPO
2025
News (4w)
16
21
Recent ratings
8
25
AORT

Artivion Inc.

Artivion Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo. It also provides E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion Inc. in January 2022. The company was founded in 1984 and is headquartered in Kennesaw, Georgia.

Latest AORT

Latest MDLN